NASDAQ$TNGX

Tango Therapeutics Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Headline financials

Total Revenue

$6.92M

Previous: $6.79M+2.0%
EPS (adj)

-$0.33

Previous: -$0.28-17.9%
Capital Expenditures

-$6.65M

Previous: -$1.14M-482.9%
Free Cash Flow

-$35.7M

Previous: -$20.7M-72.2%
Net Income

-$29.1M

Previous: -$19.6M-48.3%
Operating Income

-$29.9M

Previous: -$19.6M-52.9%
Gross Profit

$6.92M

Previous: $6.79M+2.0%
Cash & Equivalents

$100M

Previous: $205M-51.1%
Total Assets

$464M

Previous: $530M-12.4%
Stock-Based Comp

$3.82M

Previous: $3.43M+11.2%

Revenue & EPS history

Tango Therapeutics · Revenue · Quarterly

$6.92M

Q3 2022+2%vs Q3 2021
Beat estimate in 6 of 13 quarters(46%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.6%

Avg return

Earnings day

+6.7%

Avg return

5 days after

+25.8%

Avg return

30 days after

58%

11 / 19 earnings

Positive

+36.4%

Q4 2025

Best reaction

-45.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+8.6%-12.1%+31.7%
Q4 2025+36.4%+33.6%+75.1%
Q3 2025+0.2%-1.7%+23.6%
Q1 2025+17.1%+31.6%+315.8%
Q4 2024-6.5%-21.0%-36.9%
Q3 2024-45.4%-34.7%-34.7%
Q2 2024-1.8%-5.7%+20.9%
Q1 2024-0.8%-6.9%-12.1%
Q4 2023-9.7%-14.4%-17.4%
Q3 2023+3.8%-12.1%+6.6%
Q2 2023+1.2%+120.9%+113.5%
Q1 2023+6.4%+4.4%-0.3%
Q4 2022-9.4%-5.3%-21.6%
Q3 2022-5.3%+6.7%-1.3%
Q2 2022+22.4%+32.8%-8.1%
Q1 2022-7.6%+1.2%-3.8%
Q4 2021+0.3%+6.8%+1.3%
Q3 2021+0.4%+5.2%-10.7%
Q2 2021+1.1%-2.2%+49.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro